SBIR Phase I: Rapid, instrument-free Nucleic Acid Test for Pathogens and Biothreats

SBIR 第一阶段：快速、无需仪器的病原体和生物威胁核酸检测

• 批准号: 1720900
• 负责人: HyunDae Cho
• 金额: $ 22.49万
• 依托单位: CrossLife Technologies Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2018-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1720900&HistoricalAwards=false
• 关键词: SBIR; Phase; Rapid; instrument; free

This SBIR Phase I project will develop a prototype for a rapid and sensitive, point-of-care (POC) two-dimensional paper networks (2DPN) nucleic acid test for the detection of pathogens or biothreats. The proposed product is based on a disruptive platform technology called the Template Assisted Rapid Assay (TARA), which works directly on diverse biological samples without nucleic acid purification. TARA seamlessly integrates minimal sample preparation with target amplification and detection, which has been the greatest challenge in POC nucleic acid testing. The test eliminates the need for excess devices for sample collection, resource-intensive refrigerated storage and transport of samples, access to instrumentation and laboratory (with its overhead costs which are required for RT-qPCR, Reverse Transcription Polymerase Chain Reaction) tests that are the most commonly used tests for pathogen or biothreat detection currently. The company will show proof-of-concept of the device via the example of MERS-CoV detection. A microfluidic-based automated 2DPN TARA card can be applied broadly to applications for point-of-care or on-the-field nucleic acid detection of infectious agents or biothreats. The 2DPN TARA card provides the sample to answer, and easy to use, assay system.

这个SBIR第一阶段项目将开发一种快速而灵敏的医疗点(POC)二维纸质网络(2DPN)核酸检测的原型，用于检测病原体或生物制剂。拟议的产品基于一种名为模板辅助快速分析(TARA)的颠覆性平台技术，该技术直接在不同的生物样本上工作，而不需要纯化核酸。Tara将最少的样品制备与目标扩增和检测无缝集成，这一直是POC核酸测试中的最大挑战。该检测消除了对样品采集、耗费资源的冷藏样品储存和运输、获取仪器和实验室(RT-qPCR和逆转录聚合酶链式反应所需的管理费用)检测的额外设备的需要，而这些检测是目前最常用的病原体或生物碱检测检测方法。该公司将通过MERS-CoV检测的例子展示该设备的概念验证。基于微流控的自动化2DPN Tara卡可广泛应用于医疗现场或现场检测感染性病原体或生物制剂的应用。2DPN Tara卡提供了要回答的样本，并且易于使用。